Navigation Links
Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum
Date:4/17/2014

NEW YORK (17 April 2014) Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study also provides the first data that the gel is effective against multiple strains of HIV, and has a window of efficacy in the vagina against all three viruses of at least eight hours prior to exposure. A Phase 1 safety trial of the gel is set to begin enrollment in May 2014.

These findings were published today in PLOS ONE in an article entitled "A Potent Combination Microbicide that Targets SHIV-RT, HSV-2 and HPV."

The gel, known as MZC, contains two potent antiviral agents: MIV-150 and zinc acetate. MIV-150 is an enzyme inhibitor that prevents HIV-infected cells from producing new virus, and zinc acetate is an antiviral agent with known activity against HIV and HSV-2. These compounds are mixed in a base of carrageenan, a compound derived from seaweed that has also been shown to have potent activity against HPV. Infection with HSV-2 or HPV is associated with increased risk of HIV infection. Microbicides that target HIV, HSV-2, and HPV may more effectively limit HIV transmission than those that target HIV alone.

In this study, Council scientists and their partners used macaque and mouse models to examine whether MZC gel could prevent the vaginal and rectal transmission of SHIV-RT, HSV-2, and HPV. SHIV-RT is a human/simian immunodeficiency chimeric virus combining the HIV reverse transcriptase (RT) within SIV (the monkey version of HIV). MIV-150 and zinc acetate inhibit HIV-RT via different mechanisms of action. Preclinical testing in animals is required by the FDA and is important to ensure the highest level of safety and to build the evidence base for potential efficacy in humans.

"It is the versatility of MZC that makes it a desirable microbicide candidate," said Jos A. Fernndez Romero, a scientist at the Population Council and corresponding author of the paper. "It is effective against multiple viruses, can be used in both the vagina and the rectum, and retains its efficacy in the vagina over an extended period of time. In addition to the gel, we are also exploring sustained-release intravaginal rings and on-demand film-based delivery systems for MZC. There is a growing demand for microbicides that prevent multiple STIs, and we are committed to ensuring that women and men have options when choosing what works most effectively for their own protection."


'/>"/>

Contact: Melanie Boyer
mboyer@popcouncil.org
202-237-9404
Population Council
Source:Eurekalert

Related medicine news :

1. Researchers develop a new cell and animal model of inflammatory breast cancer
2. FDA Seeks to Limit Antibiotics in Animal Feed
3. Animals More Interesting to Kids Than Toys, Study Shows
4. Raucous Music May Tap Into Your Inner Animal
5. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
6. Woodbridge Animal Hospital Unleashes New Pet Care Website
7. Chicago Dog Bite Injury Lawyers Advise Dog Owners To Get Control of Their Animals, Or Be Prepared To Pay Up
8. New technique could reduce number of animals needed to test chemical safety
9. Potential treatment target identified in an animal model of pancreatic cancer
10. New animal model may lead to treatments for common liver disease
11. Lab-engineered muscle implants restore function in animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology that measures ... on the market can deliver all that rejiva can. , “Rejiva promotes relaxation and ... than the usual heart rate and steps taken”, adds Evens Augustin, CEO of Rijuven. ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is a ... versatile lower third titles with just a few clicks of the mouse," said Christina ... 30 lower third animations. Choose from various styles with accented animations, rigid boxes, simplistic ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... needy individuals and families from eight different sites throughout Miami-Dade and Broward counties. ... 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual meals ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: ... of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon ... of Water, Global Climate Change and Your Health radio program syndicated on Voice ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... that we have been designated as a Cigna Infertility Center of Excellence. The ... performance standards. , “It’s an honor to be designated a Cigna Infertility ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 1, 2016  Today, Simpson Healthcare Executives, a global ... being selected as winners of multiple awards at the ... at the PLATINUM level, Blue Zones Menu at the ... GOLD Level, and our proprietary 3ConneX Platform at the ... Executives, we are excited to showcase our new Platinum ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
(Date:12/2/2016)... 2, 2016 Allergan plc (NYSE: AGN ... on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a variable ... Company will repurchase $10 billion of its ordinary shares. Approximately ...
Breaking Medicine Technology: